Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03466502 · ClinicalTrials.gov registry record · Phase 4
Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics
A Phase 4 study of Clostridium Difficile Infection, sponsored by University of Nevada, Reno.
- Completed
- Registry status
- Phase 4
- Development phase
- 104
- Enrollment target
- 1
- Study location
NCT03466502: Completed Phase 4 study of Clostridium Difficile Infection, sponsored by University of Nevada, Reno.
NCT03466502 is a Phase 4 study of Clostridium Difficile Infection that has completed, run by University of Nevada, Reno. The registered enrollment target is 104 participants, below the 12,058-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03466502, a Phase 4 study of Clostridium Difficile Infection, has completed, sponsored by University of Nevada, Reno.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial infection.
Primary Outcome
Diarrheal illness, with at least 3 episodes of watery diarrhea over a 24 hour period and a positive toxin analysis or a positive PCR for Cdiff
Conditions Studied
Interventions
- DRUG Oral Vancomycin
Study Locations (1)
Nevada
- Renown Regional Medical Center - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2018-03-08 |
| Est. Completion | 2022-02-17 |
| Phase | Phase 4 |
What the finished NCT03466502 record still lists
NCT03466502 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 12,058-participant average among 13 other Clostridium Difficile Infection trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Clostridium Difficile Infection appearing as the primary indexed condition, and to 1 intervention - of which Oral Vancomycin is the first listed.
NCT03466502 reports a single indexed study location in Nevada.
Frequently Asked Questions
What is clinical trial NCT03466502 about?
NCT03466502 is a clinical study titled "Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics". This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial infection.
What is the current status of trial NCT03466502?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 104 participants. The study started on 2018-03-08. Estimated completion is 2022-02-17.
What conditions does trial NCT03466502 study?
This clinical trial studies the following conditions: Clostridium Difficile Infection.
What interventions are being tested in trial NCT03466502?
The interventions under investigation include: Oral Vancomycin (DRUG).
Who is sponsoring clinical trial NCT03466502?
This trial is sponsored by University of Nevada, Reno, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03466502 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridium Difficile Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03466502's enrollment target sits among peer trials
104 10th of 13 higher than 4 of 13 other Clostridium Difficile Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Clostridium Difficile Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium Difficile
RECRUITING · NA
-
Fecal Microbiota Transplantation for C Diff Infection
RECRUITING · NA
-
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
RECRUITING · Phase 2
-
Fecal Microbiota Transplant National Registry
RECRUITING
-
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
RECRUITING · Phase 2
-
Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI